SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Posting of Annual Report and AGM Notice
6 December 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health confirms that the Notice of Annual General Meeting ("AGM"), form of proxy and Annual Report and Accounts for the year ended 30 June 2023 have been posted to shareholders.
An electronic copy of the Annual Report and Accounts and the Notice of AGM are also available on the Company's website - www.skinbiotherapeutics.com/investor-relations.
The AGM will be held at 9:00am on Friday 29 December 2023 at The Clarion Hotel, Witney Way, Boldon, NE35 9PE.
-Ends-
For more information please contact:
| SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO
| Tel: +44 (0) 191 495 7325
|
| Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)
| Tel: +44 (0) 20 7220 0500
|
| Instinctif Partners (financial press) Melanie Toyne-Sewell / Jack Kincade
| Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics@instinctif.com
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps?, a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.